Nilsson AG, 2018
Sweden
To investigate if L. reuteri ATCC PTA 6475 has an effect on bone loss in older women with low bone mineral density. Primary outcome was relative change in volumetric bone mineral density (vBMD) after 12 months.
R, DB, PC 12 months
L. reuteri: 45 (1×1010 CFU) Placebo: 45
L. reuteri significantly reduced bone loss compared to placebo (p=0.047). Change in vBMD was -0.83% in the L. reuteri group and -1.85% in the placebo group.
Li P, 2022
(Substudy of Nilsson 2018) Sweden
To characterize the gut microbiome composition and function as well as serum metabolome in good responders (GR) and poor respon ders (PR) to L. reuteri ATCC PTA 6475 treatment as a secondary analysis. Results on bone density from this cohort are published in Nilsson et al. 2018).
R, DB, PC 12 months
L. reuteri: (1×1010 CFU) GR group: 10 PR group: 10
No significant difference in microbial composition at high taxonomic level between GR and PR groups at 12 months. However, at species level GR had a significant increase of SCFA-producing species, and lower abundance of E. coli than PR at 12 months.